Stephen Szabo, MD
Obstetrics & Gynecology · Pinehurst, NCNPI 1689698771
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,738 of the $79,766 with a category attached, or 82.4%. Teva Pharmaceuticals USA, Inc. accounts for 92.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $74,164 and has fallen 99.1% since, to $631 in 2025. Among obstetrics & gynecology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $336.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$74K
- Axonics, Inc.$3K
- AbbVie$493
- Novo Nordisk$457
- Boston Scientific$296
- Aspira Women's Health Inc$212
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$65,73882%
- Travel & lodging$8,42511%
- Food & beverage$5,5607%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 93 | $73,961 |
| Axonics, Inc. | 33 | $2,857 |
| AbbVie | 23 | $493 |
| Novo Nordisk | 10 | $457 |
| Boston Scientific | 5 | $296 |
| Aspira Women's Health Inc | 2 | $212 |
| Astellas Pharma US Inc | 11 | $205 |
| Caldera Medical, Inc | 1 | $137 |
| Organon | 8 | $133 |
| Laborie Medical Technologies Corp. | 1 | $123 |
| Pfizer | 6 | $88 |
| Sumitomo Pharma America, Inc. | 4 | $84 |
| Daiichi Sankyo Inc. | 5 | $77 |
| Coopersurgical, Inc. | 3 | $59 |
| Baxter Healthcare | 2 | $55 |
| Roche Diagnostics Corporation | 2 | $49 |
| Covidien LP | 2 | $43 |
| Exeltis, USA Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Hologic Sales And Service, LLC | 2 | $33 |
| Valencia Technologies Corporation | 1 | $32 |
| Mayne Pharma Commercial LLC | 1 | $32 |
| Avion Pharmaceuticals | 2 | $30 |
| Therapeuticsmd, Inc. | 2 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Smith+Nephew | 2 | $25 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Davol Inc. | 1 | $18 |
| Coloplast | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Amgen | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Lupin Inc. | 1 | $13 |
| Meditrina | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,766 in reported general payments places this provider in the 95th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 56 | $52,359 |
| MyrbetriqMirabegron | 77 | $49,477 |
| PremarinEstrogens, Conjugated | 63 | $20,953 |
| Estradiol | 298 | $16,558 |
| Estradiol (Once Weekly)Estradiol | 74 | $7,177 |
| CombipatchEstradiol/Norethindrone Acet | 12 | $2,983 |
| Estradiol (Twice Weekly)Estradiol | 23 | $1,876 |
| ProgesteroneProgesterone, Micronized | 29 | $1,080 |
| Risedronate Sodium | 15 | $549 |
| Clobetasol Propionate | 27 | $437 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $391 |
| Ibuprofen | 71 | $323 |
| ValacyclovirValacyclovir Hcl | 12 | $274 |
| Bethanechol Chloride | 16 | $256 |
| Mometasone Furoate | 18 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $52,35956 claims |
| Astellas Pharma US IncMyrbetriq | $205 | $49,47777 claims |
| PfizerPremarin | $88 | $20,95363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
Other obstetrics & gynecology in Pinehurst
- Jerry MatkinsCharlotte$481K
- Laura McKainWilmington$475K
- Leslie Hansen-LindnerCharlotte$372K
- Robin MatthewsClyde$217K
- Haywood BrownDurham$165K
- Jack IngeRaleigh$157K
- Geeta SwamyDurham$142K
- Karie LafleurAsheville$135K
- Ty RobinsonHigh Point$114K
- Shan BiscetteCharlotte$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.